Comments

Inozyme Pharma

INZYNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$5.33
0.01000.19%
At Close: -
$5.33
00.00%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Inozyme Pharma (INZY) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$23.00
Lowest Price Target1
$6.00
Consensus Price Target1
$14.33

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Inozyme Pharma (NASDAQ:INZY) Stock, Analyst Ratings, Price Targets, Forecasts

Inozyme Pharma Inc has a consensus price target of $14.33 based on the ratings of 6 analysts. The high is $23 issued by Needham on May 8, 2024. The low is $6 issued by Jefferies on March 23, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Wells Fargo, and Needham on July 2, 2024, May 30, 2024, and May 8, 2024, respectively. With an average price target of $17 between HC Wainwright & Co., Wells Fargo, and Needham, there's an implied 218.95% upside for Inozyme Pharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jan
0
0
0
0
Mar
0
0
0
0
Apr
1
May
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Wells Fargo
Needham
B of A Securities
Wedbush

1calculated from analyst ratings

Analyst Ratings for Inozyme Pharma

Buy NowGet Alert
07/02/2024Buy Now162.66%HC Wainwright & Co.
Edward White
$14 → $14ReiteratesBuy → BuyGet Alert
05/30/2024Buy Now162.66%Wells Fargo
Tiago Fauth
 → $14Initiates → OverweightGet Alert
05/08/2024Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now162.66%B of A Securities
Tazeen Ahmad
$16 → $14MaintainsBuyGet Alert
03/13/2024Buy Now200.19%HC Wainwright & Co.
Edward White
$16 → $16MaintainsBuyGet Alert
03/12/2024Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
01/30/2024Buy Now181.43%Wedbush
David Nierengarten
 → $15ReiteratesOutperform → OutperformGet Alert
11/08/2023Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
09/27/2023Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
09/08/2023Buy Now181.43%Wedbush
David Nierengarten
 → $15MaintainsOutperformGet Alert
08/09/2023Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now200.19%HC Wainwright & Co.
Edward White
 → $16ReiteratesBuy → BuyGet Alert
08/04/2023Buy Now200.19%HC Wainwright & Co.
Edward White
$19 → $16MaintainsBuyGet Alert
07/27/2023Buy Now331.52%Needham
Joseph Stringer
 → $23ReiteratesBuy → BuyGet Alert
05/10/2023Buy Now331.52%Needham
Joseph Stringer
 → $23Reiterates → BuyGet Alert
04/19/2023Buy Now331.52%Needham
Joseph Stringer
 → $23Reiterates → BuyGet Alert
03/23/2023Buy Now12.57%Jefferies
Suji Jeong
$4.5 → $6UpgradeHold → BuyGet Alert
03/23/2023Buy Now331.52%Needham
Joseph Stringer
 → $23Reiterates → BuyGet Alert
02/17/2023Buy Now275.23%HC Wainwright & Co.
Edward White
 → $20Reiterates → BuyGet Alert
02/17/2023Buy Now331.52%Needham
Joseph Stringer
 → $23Reiterates → BuyGet Alert
05/26/2022Buy Now-6.19%Jefferies
Suji Jeong
 → $5Initiates → HoldGet Alert
05/11/2022Buy Now275.23%HC Wainwright & Co.
Edward White
$33 → $20MaintainsBuyGet Alert
03/16/2022Buy Now369.04%Wedbush
David Nierengarten
$35 → $25MaintainsOutperformGet Alert
02/07/2022Buy Now519.14%HC Wainwright & Co.
Edward White
 → $33Initiates → BuyGet Alert
11/29/2021Buy Now331.52%Needham
Joseph Stringer
—Initiates → BuyGet Alert

FAQ

Q

What is the target price for Inozyme Pharma (INZY) stock?

A

The latest price target for Inozyme Pharma (NASDAQ:INZY) was reported by HC Wainwright & Co. on July 2, 2024. The analyst firm set a price target for $14.00 expecting INZY to rise to within 12 months (a possible 162.66% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Inozyme Pharma (INZY)?

A

The latest analyst rating for Inozyme Pharma (NASDAQ:INZY) was provided by HC Wainwright & Co., and Inozyme Pharma reiterated their buy rating.

Q

When was the last upgrade for Inozyme Pharma (INZY)?

A

The last upgrade for Inozyme Pharma Inc happened on March 23, 2023 when Jefferies raised their price target to $6. Jefferies previously had a hold for Inozyme Pharma Inc.

Q

When was the last downgrade for Inozyme Pharma (INZY)?

A

There is no last downgrade for Inozyme Pharma.

Q

When is the next analyst rating going to be posted or updated for Inozyme Pharma (INZY)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.

Q

Is the Analyst Rating Inozyme Pharma (INZY) correct?

A

While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a reiterated with a price target of $14.00 to $14.00. The current price Inozyme Pharma (INZY) is trading at is $5.33, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch